Pfizer backs CRISPR biotech Caribou in latest cell therapy investment
BioPharma Drive: Drug Pricing
JULY 6, 2023
Five years after helping launch Allogene Therapeutics, Pfizer is backing another developer of “off-the-shelf” cell therapies in a deal that gives the drugmaker the chance to acquire a multiple myeloma treatment.
Let's personalize your content